Regulatory approval

Published by the European Medicines Agency. Approved

Aumseqa as monotherapy is indicated for the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC.

This is written in the approval document.

Citation

SFL Pharmaceuticals Deutschland GmbH. Aumseqa (aumolertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/aumseqa-epar-product-information_en.pdf. Revised February 2026. Accessed August 2, 2026.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) EGFR p.T790M Non-Small Cell Lung Cancer Aumolertinib

Contributions

Date Contributor Description
2026-08-02 Van Allen lab Initial curation of into moalmanac-db
2026-02-12 European Medicines Agency Indication received approval from the European Commission.